## Stig P Cramer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8597956/publications.pdf

Version: 2024-02-01

932766 1281420 12 711 10 11 citations h-index g-index papers 12 12 12 1414 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neurolmage: Clinical, 2014, 4, 182-189.	1.4	180
2	Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain, 2017, 140, 1633-1642.	3.7	105
3	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
4	Accurate Determination of Blood–Brain Barrier Permeability Using Dynamic Contrast-Enhanced T1-Weighted MRI: A Simulation and ⟨i⟩in vivo⟨/i⟩ Study on Healthy Subjects and Multiple Sclerosis Patients. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1655-1665.	2.4	90
5	Permeability of the blood–brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain, 2015, 138, 2571-2583.	3.7	75
6	Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis. PLoS ONE, 2013, 8, e77163.	1.1	55
7	Blood–brain barrier permeability measured using dynamic contrastâ€enhanced magnetic resonance imaging: a validation study. Journal of Physiology, 2019, 597, 699-709.	1.3	47
8	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
9	Brain capillary transit time heterogeneity in healthy volunteers measured by dynamic contrastâ€enhanced T <sub>1</sub> â€weighted perfusion MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 1809-1820.	1.9	16
10	Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis. Annals of Neurology, 2018, 83, 902-914.	2.8	11
11	Cerebrovascular Reactivity and Neurovascular Coupling in Multiple Sclerosis—A Systematic Review. Frontiers in Neurology, 2022, 13, .	1.1	3
12	Physical and Physiological Principles of Perfusion and Permeability. Advances in Magnetic Resonance Technology and Applications, 2020, , 269-294.	0.0	0